UnitedHealth Group UNH Optum Rx — D&A

Other segment segments

Similar metrics at other companies

OPKPharmaceutical — D&A

$18.51M+2.0%

CVSPharmacy & Consumer Wellness — D&A

$406M+5.7%

AMP

AMPHPharmaceutical Products — D&A

$14.35M+5.4%

VAN

VANIBiopharm Division — D&A

$130K+31.3%

CAHPharmaceutical and Specialty Solutions — D&A

$70M+59.1%

THCAmbulatory Care — D&A

$41M+5.1%

Questions, answered.

What is UnitedHealth Group's optum rx — D&A?

UnitedHealth Group (UNH) reported optum rx — D&A of $173M in Q1 2026.

How has UnitedHealth Group's optum rx — D&A changed year-over-year?

UnitedHealth Group's optum rx — D&A decreased by 18.0% year-over-year, from $211M to $173M.

What is the long-term trend for UnitedHealth Group's optum rx — D&A?

Over 4 years (2021 to 2025), UnitedHealth Group's optum rx — D&A has grown at a 9.1% compound annual growth rate (CAGR), from $597M to $845M.

What does optum rx — D&A mean?

This metric represents the non-cash expense allocated to the Optum Rx pharmacy care services segment for the wear and tear of tangible assets and the systematic write-down of intangible assets over their useful lives. It reflects the capital intensity of the pharmacy benefit management operations, including investments in technology platforms, distribution infrastructure, and acquired customer relationships. Monitoring this figure helps investors understand the segment's ongoing capital expenditure requirements and the impact of historical acquisitions on current earnings.